Assessing the diagnostic value of zonulin as a biomarker for intestinal permeability in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus
DOI:
https://doi.org/10.14739/2310-1210.2023.5.280829Keywords:
zonulin, intestinal permeability, non-alcoholic fatty liver disease, bacterial overgrowth syndrome, type 2 diabetes mellitusAbstract
The aim of the study was to assess the diagnostic value of serum zonulin concentrations in patients with metabolic-associated fatty liver disease (МAFLD) in combination with type 2 diabetes mellitus (T2DM).
Materials and methods. The study involved 93 patients with MAFLD in combination with T2DM, who were examined and allocated to two groups. Group 1 consisted of 48 patients with non-alcoholic steatohepatitis (NASH) in combination with T2DM without small intestinal bacterial overgrowth (SIBO) syndrome. Group 2 comprised 45 patients with NASH in combination with T2DM and SIBO. The control group consisted of 25 apparently healthy persons. The ELISA method was used for quantitative determination of serum zonulin.
Results. When comparing parameters of liver functional activity and ultrasonographic findings of liver steatosis and fibrosis, a significant increase in the activity of ALT and AST was revealed in Group 1 – 67.22 ± 2.25 U/l and 52.97 ± 1.04 U/l (p < 0.001) and in Group 2 – 69.20 ± 1.52 U/l and 54.82 ± 1.10 U/l (p < 0.001) compared to those in the control group – 18.00 ± 1.01 U/l and 18.96 ± 0.82 U/l (p < 0.001) respectively, as well as an increase in the ultrasound attenuation coefficient (UAC) in patients of Groups 1 and 2 amounting to 2.94 ± 0.03 dB/cm and 2.92 ± 0.04 dB/cm, respectively, and also the liver stiffness (LS) in Group 1 – 8.06 ± 0.07 kPa and in Group 2 – 8.00 ± 0.06 kPa compared to those in the control group (p < 0.001).
When measuring the level of serum zonulin, a significant increase was revealed in patients of Group 1 – 61.69 ± 1.04 ng/ml and Group 2 – 89.39 ± 1.30 ng/ml compared to that in the control group – 16.76 ± 1.47 ng/ml (p < 0.001). Analyzing correlation coefficients in patients of Groups 1 and 2, a positive linear moderate association was found between the serum zonulin concentration and the activity of ALT, AST and UAC and LS.
Conclusions. The study resultsobtained have demonstrated the great diagnostic value of serum zonulin as a biomarker of intestinal permeability in NASH patients in combination with T2DM, and with or without SIBO.
References
Eslam, M., Sanyal, A. J., George, J., & International Consensus Panel (2020). MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 158(7), 1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312
Younossi, Z. M., Rinella, M. E., Sanyal, A. J., Harrison, S. A., Brunt, E. M., Goodman, Z., Cohen, D. E., & Loomba, R. (2021). From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology, 73(3), 1194-1198. https://doi.org/10.1002/hep.31420
Mendez-Sanchez, N., Arrese, M., Gadano, A., Oliveira, C. P., Fassio, E., Arab, J. P., Chávez-Tapia, N. C., Dirchwolf, M., Torre, A., Ridruejo, E., Pinchemel-Cotrim, H., Castellanos Fernández, M. I., Uribe, M., Girala, M., Diaz-Ferrer, J., Restrepo, J. C., Padilla-Machaca, M., Dagher, L., Gatica, M., Olaechea, B., … Silva, M. (2021). The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The lancet. Gastroenterology & hepatology, 6(1), 65-72. https://doi.org/10.1016/S2468-1253(20)30340-X
Shiha, G., Alswat, K., Al Khatry, M., Sharara, A. I., Örmeci, N., Waked, I., Benazzouz, M., Al-Ali, F., Hamed, A. E., Hamoudi, W., Attia, D., Derbala, M., Sharaf-Eldin, M., Al-Busafi, S. A., Zaky, S., Bamakhrama, K., Ibrahim, N., Ajlouni, Y., Sabbah, M., Salama, M., … Soliman, R. (2021). Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. The lancet. Gastroenterology & hepatology, 6(1), 57-64. https://doi.org/10.1016/S2468-1253(20)30213-2
Cui, Y., Wang, Q., Chang, R., Zhou, X., & Xu, C. (2019). Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. Journal of agricultural and food chemistry, 67(10), 2754-2762. https://doi.org/10.1021/acs.jafc.9b00080
Fasano, A. (2020). All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Research, 9, F1000 Faculty Rev-69. https://doi.org/10.12688/f1000research.20510.1
Miranda-Ribera, A., Ennamorati, M., Serena, G., Cetinbas, M., Lan, J., Sadreyev, R. I., Jain, N., Fasano, A., & Fiorentino, M. (2019). Exploiting the Zonulin Mouse Model to Establish the Role of Primary Impaired Gut Barrier Function on Microbiota Composition and Immune Profiles. Frontiers in immunology, 10, 2233. https://doi.org/10.3389/fimmu.2019.02233
Barbara, G., Barbaro, M. R., Fuschi, D., Palombo, M., Falangone, F., Cremon, C., Marasco, G., & Stanghellini, V. (2021). Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Frontiers in nutrition, 8, 718356. https://doi.org/10.3389/fnut.2021.718356
Caviglia, G. P., Rosso, C., Ribaldone, D. G., Dughera, F., Fagoonee, S., Astegiano, M., & Pellicano, R. (2019). Physiopathology of intestinal barrier and the role of zonulin. Minerva biotecnologica, 31(3), 83-92. https://doi.org/10.23736/S1120-4826.19.02554-0
Wood Heickman, L. K., DeBoer, M. D., & Fasano, A. (2020). Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity. Diabetes/metabolism research and reviews, 36(5), e3309. https://doi.org/10.1002/dmrr.3309
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., Gabbay, R. A., … on behalf of the American Diabetes Association (2023). 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes care, 46(Suppl 1), S19-S40. https://doi.org/10.2337/dc23-S002
Wang, Y., & Liu, Y. (2021). Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell. Journal of gastroenterology and hepatology, 36(10), 2706-2714. https://doi.org/10.1111/jgh.15512
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
